Multiply Labs and Akron Bio Partner to Automate the Use of cGMP-Compliant Liquid Cytokines in Cell Therapy Manufacturing
Akron Biotech (Akron), a leading supplier of critical inputs for cell and gene therapies, announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted Akron Eligibility Confirmation for its cGMP virus inactivated human fibronectin. The PMDA Notification (No. 1205004) indicates that the product – including all raw materials and consumables used in the manufacturing process – complies with requirements for animal and human-derived materials defined in the Japanese Standards for Biological Raw Materials (JSBRM) issued by the Ministry of Health, Labour and Welfare (MHLW) and that none of the product’s components present safety concerns (i.e. toxic substances, deleterious substances, heavy metals, physiologically active substances other than the fibronectin).
Akron Bio Receives Eligibility Confirmation from PMDA in Japan for the Commercialization of Virus Inactivated Human Fibronectin in Clinical Cell Therapy Manufacturing
Akron Bio Appoints Christopher Murphy as Chief Executive Officer
BOCA RATON, Fla.--(BUSINESS WIRE)--Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions™ (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows. Akron’s industry-leading liquid Recombinant Human Interleukin-2 (rHu IL-2), Human AB Serum Converted from Octaplas®, and Human Serum Albumin 25% Solution are now available in single-use, ready-to-use bags with weldable tubing.
SARASOTA, Fla.--(BUSINESS WIRE)--Akron Bio, a leading developer and manufacturer of critical building blocks used by biopharma to produce advanced therapies for the prevention and treatment of cardiovascular diseases and cancers, today launched a new, state-of-the-art cGMP (Current Good Manufacturing Practice) plasmid DNA manufacturing facility in Sarasota, Florida.
BOCA RATON, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop and manufacture cGMP nucleases.
Akron Biotech has signed an exclusive global agreement with Switzerland-based Octapharma to produce virally inactivated Human AB Serum for the cell therapy market using the latter’s Octaplas.
BOCA RATON, FL – January 20, 2021 – Akron Biotechnology, LLC (Akron Biotech), today announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma. Akron Biotech is a leading manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialization. Switzerland-based Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
BOCA RATON, Fla.--(BUSINESS WIRE)--Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients. Akron Biotech provides cGMP-compliant solutions to support the development and commercialization of advanced therapies.